DALLAS, May 28, 2015 /PRNewswire-iReach/ -- The report "Hepatitis D – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Hepatitis D, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Photo - http://photos.prnewswire.com/prnh/20150528/219093

Hepatitis D or delta hepatitis is caused by the hepatitis delta virus (HDV), a defective RNA virus. Hepatitis D, which can be acute or chronic, is uncommon in the United States. HDV is transmitted through percutaneous or mucosal contact with infectious blood and can be acquired either as a coinfection with HBV or as superinfection in persons with HBV infection. The symptoms of hepatitis B and hepatitis D are similar.

Companies discussed in this Hepatitis D – Pipeline Review, H1 2015 report include:

• Alnylam Pharmaceuticals, Inc.
• BioDiem Ltd
• Biogenomics Limited
• Eiger BioPharmaceuticals, Inc.
• Globeimmune, Inc.
• Johnson & Johnson
• REPLICor Inc.
• SomaGenics Inc.

Drugs profiles discussed in this report includes ALN-HDV, EBP-921, GI-18000, hepatitis D vaccine, interferon alfa-2b (recombinant), lonafarnib, Myrcludex-B, REP-9-AC', RNAi Oligonucleotide for Hepatitis D, tipifarnib. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=386037 . (This is a premium report priced at US$2000 for a single user License.)

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.

Featured News & Press Releases cover by this report include:

• Apr 13, 2015: Eiger BioPharmaceuticals Announces Abstracts and Presentations of Lonafarnib Data in Hepatitis Delta at the European Association for the Study of the Liver Conference - April 22 to 26, 2015
• Apr 10, 2015: Replicor to Present at the 2015 Lancet Viral Hepatitis Conference
• Apr 02, 2015: Replicor Announces Completion of Enrollment in Phase II Trial
• Feb 23, 2015: Eiger BioPharmaceuticals Announces Presentation of Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib
• Dec 22, 2014: Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting
• Dec 22, 2014: Eiger Bio Receives Orphan Designation for Lonafarnib, a First In Class, Investigational Treatment for Hepatitis Delta Virus (HDV) Infection
• Oct 01, 2014: REPLICor announces initiation of its Phase II clinical trial with REP 2139-Ca in combination with Pegasys in patients with hepatitis B / hepatitis D co-infection

Scope of this report includes: The report provides a snapshot of the global therapeutic landscape of Hepatitis D; reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for Hepatitis D and enlists all their major and minor projects, summarizes all the dormant and discontinued pipeline projects; A review of the Hepatitis D products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; A detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Hepatitis D pipeline on the basis of target, MoA, route of administration and molecule type as well as Latest news and deals relating related to pipeline products.

Explore more reports on Hepatitis Drugs at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/hepatitis-drugs .

More reports on Hepatitis Drugs

Global Hepatitis A Vaccine Industry Report 2015

The report focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Hepatitis A Vaccine industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered.

Hepatitis C – Pipeline Review, H1 2015

This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects.

Alcoholic Hepatitis – Pipeline Review, H1 2015

This report provides comprehensive information on the therapeutic development for Alcoholic Hepatitis. Companies discussed in this report include Alfact Innovation, Conatus Pharmaceuticals Inc., Generon (Shanghai) Corporation Ltd., Immuron Limited, Intercept Pharmaceuticals, Inc., Oncozyme Pharma Inc.

About Us:

RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers. Call +1 888 391 5441 with your research requirements or email the details on sales@rnrmarketresearch.com This e-mail address is being protected from spambots. You need JavaScript enabled to view it and we would be happy to help you find the business intelligence that you need.

Media Contact: Ritesh Tiwari, RnR Market Research, +1888391544, sales@rnrmarketresearch.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE RnR Market Research